Introduction: Pancreatic neuroendocrine tumours (PNETs) are a heterogeneous group of rare pancreatic neoplasms often diagnosed with distant metastases, which are associated with significantly poorer prognosis. Recurrent somatic mutations, chromosomal aberrations and gene expression signatures in PNETs have been described, but the clinical significance of these molecular changes is still poorly understood, and the clinical outcomes of PNET patients remain highly variable.
Aim(s): Our study aims to identify the molecular factors that contribute to tumour progression and metastasis in PNETs and poor clinical outcomes in PNET patients.
Materials and methods: The genomic and transcriptomic profiles of liver metastases from five PNET patients were previously analyzed as part of an ongoing clinical trial at the BC Cancer Agency (clinicaltrials.gov ID: NCT02155621). In addition to the analyses of the metastatic specimens, we used the SP3-CTP proteome profiling method developed in-house to quantify global proteome changes among primary PNET specimens from forty PNET patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Chi-Fu Kevin Yang
Yang K C
, Wong H L
, Shen Y
, Colborne S
, Kalloger S
, Karasinska J
, Laskin J
, Morin G B
, Marra M A
, Schaeffer D F
, Renouf D J
, Gorski S M
To read results and conclusion, please login ...
Further abstracts you may be interested in